Contract facts
UnrestrictedResearch and Development for Randomized Controlled Trial of Sildenafil Citrate for Treatment of Cerebrovascular Dysfunc… is a federal Unrestricted award for W4pz Usa Med Rsch Acquis Act held by Trustees of the University of Pennsylvania, the. Estimated value $2.9M ($2.9M obligated). Current period of performance ends Dec 13, 2026. Last award drew 102 bidders. Place of performance: PHILADELPHIA PA. Related solicitation W81XWH21STBIP.
Research and development for randomized controlled trial of sildenafil citrate for treatment of cerebrovascular dysfunction in chronic traumatic brain injury. Latest action is a modification.
Recompete timing
PublicCurrent PoP ends Dec 13, 2026 (53 days remaining). Agencies typically plan 12–18 months ahead — at 1.7 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on W81XWH22C0139? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordTrustees of the University of Pennsylvania, the — $50.2M obligated across 116 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract W81XWH22C0139?
W81XWH22C0139 (Research and development for randomized) is a W4pz Usa Med Rsch Acquis Act award with a potential value of $2.9M, currently held by Trustees of the University of Pennsylvania, the. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is W81XWH-22-C-0139?
W81XWH-22-C-0139 is the dashed form of PIID W81XWH22C0139 (Research and development for randomized), held by Trustees of the University of Pennsylvania, the. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded W81XWH22C0139?
W4pz Usa Med Rsch Acquis Act awarded W81XWH22C0139 to Trustees of the University of Pennsylvania, the (potential $2.9M).
Who is the incumbent on W81XWH22C0139?
Trustees of the University of Pennsylvania, the is the incumbent with $50.2M across 116 related awards in SCOUT’s public footprint. The current period of performance ends Dec 13, 2026.
When does Trustees of the University of Pennsylvania, the’s W81XWH22C0139 come up for recompete?
SCOUT tracks a period-of-performance end of Dec 13, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on W81XWH22C0139? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.